Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Management Call

Slingshot members are talking to management! The topic is:

Understanding Summit's Leadership Role in Creating the Next Generation of Antibiotics: A Conversation with Management

Ticker(s): SMMT

Who's the expert?

Name: Glyn Edwards & David Roblin

Glyn Edwards:

  • Chief Executive Officer, Summit Therapeutics
  • Thirty-year career in the life sciences industry, during which time he has held a number of senior executive and business development roles. 
  • Prior to joining Summit, he was interim Chief Executive Officer of the UK trade body the BioIndustry Association (BIA) and Chief Executive Officer at Antisoma plc for 13 years, and Vice President of Business Development at Therapeutic Antibodies Ltd.  

David Roblin:

  • Chief Operating and Medical Officer, Summit Therapeutics
  • Has brought many medicines in several therapy areas through R&D to commercialisation, including in anti-infectives azithromycin, ciprofloxacin, moxifloxacin, voriconazole and maraviroc.
  • Prior to joining Summit, he was Chief Operating Officer and Director of Scientific Translation at the Francis Crick Institute in London,  Head of Research and Chief Medical Officer for Europe R&D, and Head of Therapy Area for Anti-infectives at Bayer AG.

Interview Questions
Q1.

Can we start with a short introduction of both your backgrounds, and how you've come to work at Summit?

Added By: joe_mccann
Q2.

Let's start with your lead asset. Can you provide an update on the Ridinilazole trial, what you've done to try and speed enrollment and anything you've learned from the Phase 2 that has shaped the Phase 3?

Added By: joe_mccann
Q3.

How are you thinking about the commercial considerations for an antibiotic? How are payors responding to your preliminary conversations?

Added By: joe_mccann
Q4.

If hospitals are going to be a critical decision makers in formulary access and prescribing, what are the key arguments that you'll be making to them?

Added By: joe_mccann
Q5.

Broadly looking at the recent launches of antibiotics, what do you think those companies have done wrong. What lessons have you learned and built into your development and launch strategy to differentiate yourself?

Added By: joe_mccann
Q6.

A criticism I've heard about the antibiotic space generally is that it will take large policy changes to reward innovation. Once we see that actually happen, I'll take a look at names in the space again.

  • Do you think that criticism is fair? If not, what do you say to it?

Added By: joe_mccann
Q7.

What role do you see PCR identification of infection type playing in treating patients going forward?

Added By: joe_mccann
Q8.

I saw you announced your first pipeline asset from the Discover platform. What will we see from Discover over the next few years and why do you call it a platform technology?

Added By: joe_mccann

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.